Patients with premalignant or malignant myeloid conditions. Full blood counts including differential white cell and platelet counts should be monitored. Treatment should be withdrawn in patients who develop signs of pulmonary infiltration. Splenic rupture following administration of granulocyte-colony stimulating factors has been reported; monitor spleen size.
Be cautious in using White-C to patients suffering from myeloid proliferation (eg, acute leukemia).